User login
Key clinical point: In a nationwide cohort of patients with inflammatory bowel disease (IBD), vedolizumab showed similar therapeutic efficacy among elderly and younger patients, with a similar proportion of patients in steroid-free remission after vedolizumab initiation.
Major finding: The proportion of patients in steroid-free remission while still on vedolizumab during the 6- to 12-month period after vedolizumab initiation was not significantly different among patients younger than 60 years of age (younger group; 46.8%) and those aged 60 years or older (elderly group; 40.1%; P = .2374). IBD-related hospitalization (P = .9737) and surgeries (P = .9851) within 1 year were similar between younger and elderly groups.
Study details: Findings are from a retrospective cohort study of 568 patients with IBD from the US national Veterans Affairs Healthcare System. Patients were categorized into elderly (n=279) and younger (n=289) groups based on their age at vedolizumab initiation.
Disclosures: The study was supported by Takeda Pharmaceutical Company Limited. N Khan declared receiving an unrestricted research grant from Pfizer, Luitpold, Takeda Pharmaceuticals, and Samsung BioEpis. Other authors had no disclosures.
Source: Khan N et al. Inflamm Bowel Dis. 2021 Jul 10. doi: 10.1093/ibd/izab163.
Key clinical point: In a nationwide cohort of patients with inflammatory bowel disease (IBD), vedolizumab showed similar therapeutic efficacy among elderly and younger patients, with a similar proportion of patients in steroid-free remission after vedolizumab initiation.
Major finding: The proportion of patients in steroid-free remission while still on vedolizumab during the 6- to 12-month period after vedolizumab initiation was not significantly different among patients younger than 60 years of age (younger group; 46.8%) and those aged 60 years or older (elderly group; 40.1%; P = .2374). IBD-related hospitalization (P = .9737) and surgeries (P = .9851) within 1 year were similar between younger and elderly groups.
Study details: Findings are from a retrospective cohort study of 568 patients with IBD from the US national Veterans Affairs Healthcare System. Patients were categorized into elderly (n=279) and younger (n=289) groups based on their age at vedolizumab initiation.
Disclosures: The study was supported by Takeda Pharmaceutical Company Limited. N Khan declared receiving an unrestricted research grant from Pfizer, Luitpold, Takeda Pharmaceuticals, and Samsung BioEpis. Other authors had no disclosures.
Source: Khan N et al. Inflamm Bowel Dis. 2021 Jul 10. doi: 10.1093/ibd/izab163.
Key clinical point: In a nationwide cohort of patients with inflammatory bowel disease (IBD), vedolizumab showed similar therapeutic efficacy among elderly and younger patients, with a similar proportion of patients in steroid-free remission after vedolizumab initiation.
Major finding: The proportion of patients in steroid-free remission while still on vedolizumab during the 6- to 12-month period after vedolizumab initiation was not significantly different among patients younger than 60 years of age (younger group; 46.8%) and those aged 60 years or older (elderly group; 40.1%; P = .2374). IBD-related hospitalization (P = .9737) and surgeries (P = .9851) within 1 year were similar between younger and elderly groups.
Study details: Findings are from a retrospective cohort study of 568 patients with IBD from the US national Veterans Affairs Healthcare System. Patients were categorized into elderly (n=279) and younger (n=289) groups based on their age at vedolizumab initiation.
Disclosures: The study was supported by Takeda Pharmaceutical Company Limited. N Khan declared receiving an unrestricted research grant from Pfizer, Luitpold, Takeda Pharmaceuticals, and Samsung BioEpis. Other authors had no disclosures.
Source: Khan N et al. Inflamm Bowel Dis. 2021 Jul 10. doi: 10.1093/ibd/izab163.